Results 191 to 200 of about 51,036 (300)

A FAERS pharmacovigilance analysis of dementia-related adverse event reports. [PDF]

Medicine (Baltimore)
Tao T, Liu B, Tao C, Chen W, Li R, Mao S, Wang K, Zhou M, Liu X.   +8 more
europepmc   +1 more source

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Adverse Drug Reactions: Building Drug Safety Beyond Marketing Authorisation. [PDF]

J Clin Med
Belančić A, Mudnić I.
europepmc   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Immune checkpoint inhibitor-related thyroid dysfunction during treatment of lung cancer: a disproportionality analysis based on the FDA adverse event reporting system. [PDF]

Front Immunol
Tan Y, Song Q.
europepmc   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

DU-Vigilance; Capturing Unsuspected Problems in Drug Utilization. [PDF]

Pharmacoepidemiol Drug Saf
Hallas J, Harbi H, Delvin T, Rasmussen L.   +3 more
europepmc   +1 more source

Zopiclone-associated hallucinations: a case report and database pharmacovigilance study. [PDF]

Front Psychiatry
Zhang P, Zhang R, Gao Y, Wei C, Zhao Q, Yang Q, Diao J.   +6 more
europepmc   +1 more source

Large Language Models in Adverse Drug Reaction Detection and Pharmacovigilance: A Systematic Review of Current Applications, Challenges, and Future Directions. [PDF]

Diagnostics (Basel)
Kim TY, Oh WS, Jeong DH.
europepmc   +1 more source